Navigation Links
Osteotech Reports 2008 Third Quarter Financial Results
Date:11/7/2008

EATONTOWN, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, reported today that revenue for the three months ended September 30, 2008 was $24.1 million compared to $25.7 million for the three months ended September 30, 2007. The decline in third quarter 2008 revenue compared to the prior year was primarily driven by a $2.8 million reduction in private label DBM revenue, which was partially offset by a 6% increase in our base line revenue, which includes our Grafton, Xpanse, Plexur and traditional tissue franchises. Gross margin was 54% and 55% in the third quarter of 2008 and 2007, respectively. Net income for the three months ended September 30, 2008 was $58 thousand compared to net income of $1.6 million, or $.09 diluted earnings per share, for the third quarter of 2007.

Revenue for the nine months ended September 30, 2008 increased 2% to $79.2 million from $77.3 million for the nine months ended September 30, 2007. The revenue growth in 2008 compared to 2007 is mainly driven by a 6% increase in our base line revenue and $1.0 million in incremental revenue from the processing of donors, partially offset by a $3.1 million decline in private label DBM revenue. Gross margin was 53% for the first nine months of 2008 compared to 51% for the first nine months of 2007. Net income for the nine months ended September 30, 2008 was $2.6 million, or $.15 diluted earnings per share, compared to net income of $1.8 million, or $.10 diluted earning per share, for the same period in the prior year. Net income in 2008 included $1.0 million associated with the settlement of certain litigation, while net income for 2007 was negatively impacted by cost
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... and the HAGUE, Netherlands ... two-year results of LES Stimulation therapy for chronic gastro-esophageal ... journal Surgery [ Surgery . 2015; ... of its minimally-invasive therapy. The study ... duration of 11 years and taking prescribed daily proton ...
(Date:3/25/2015)... , March 25, 2015  18 piglets born ... intense research by scientists in the College of Agriculture ... represent a breakthrough in the field of genetic ... the Department of Animal & Avian Sciences (ANSC) and ... ANSC, successfully produced genome-edited pigs using a recently ...
(Date:3/25/2015)... 25, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announces ... its target therapy drug candidate ENMD-2076 in triple-negative breast ... of Medical Sciences in Beijing , ...
(Date:3/25/2015)... March 25, 2015 The ... on the basis of products, technology, platform, ... this report are radar, laser, infra-red, microwave, ... video guidance systems, terrain mapping systems, and ... data Tables and 60 Figures spread through ...
Breaking Biology Technology:EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... in ... platelets, WORCESTER, Mass., Sept. ... bacterial contaminants in,blood cells and tissue, has received 510 (k) clearance for ... This provides,Verax authorization to market the device, which cuts the detection time ...
... 19 Protalix,BioTherapeutics, Inc. (Amex: PLX ), ... Chief Executive Officer, will present at the UBS ... York on Monday, September,24, 2007, at 9:30 a.m. ... live via webcast at, http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924 .,Following the live ...
... Md., Sept. 19 Stem cell company,Neuralstem, Inc. ... has received notice,that the United States Patent and ... the reexamination of the four StemCells, Inc. (Nasdaq:,STEM) ... ) "The Patent Office has rejected ...
Cached Biology Technology:Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference 2Patent Office Rules in Neuralstem's Favor in Dispute with StemCells, Inc. 2Patent Office Rules in Neuralstem's Favor in Dispute with StemCells, Inc. 3
(Date:3/5/2015)... In Brazil , cloud computing is fast ... and 42 percent planning to invest in them by the ... the companies will be investing in these solutions for the ... the region are currently opting for the private cloud model, ... attention in the coming years. This trend is in line ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... that slows the aging process. The biologists, ... increases the activity of mitochondria, the tiny power generators in ... live and die. "We took this gene ... the fly and asked whether this impacts the aging process," ...
... Mass., Nov. 9, 2011 The Children,s Hospital ... institute, today announced they have formed a partnership, ... bioinformatics analysis at a newly established, state-of-the-art Joint ... focus on the discovery of genes underpinning rare ...
... Almond, Joseph J. Doyle, Jr., Amanda E. Kowalski and ... Award for their paper entitled "Estimating Marginal Returns to ... The authors applied a cutting-edge econometric methodology to evaluate ... They found compelling evidence that such care enables very ...
Cached Biology News:UCLA biologists slow the aging process in fruit flies 2UCLA biologists slow the aging process in fruit flies 3The Children's Hospital of Philadelphia and BGI Announce Partnership and New Joint Genome Center to Target Pediatric Diseases 2The Children's Hospital of Philadelphia and BGI Announce Partnership and New Joint Genome Center to Target Pediatric Diseases 3
Trypsin (Pig Pancreas) (TPCK Treated, Highly Purified)...
Homo sapiens palladin...
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: